This inventor holds 1 USPTO granted patent and 7 published patent applications. Top assignees: Institut Pasteur, Spikimm. Active years: 2025.
Company Filing History:
1 out of 897 
1 out of 1 Years Active: 2025
Title: Antoine Pau: Innovator in Monoclonal Antibodies
Introduction
Antoine Pau is a notable inventor based in Paris, France. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work has implications for the diagnosis and treatment of viral infections, including COVID-19.
Latest Patents
Antoine Pau holds a patent for "Broadly SARS-CoV-2 neutralizing monoclonal antibodies and uses thereof." This invention relates to antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2). Specifically, it focuses on human neutralizing monoclonal antibodies that possess a broad neutralization spectrum. These antibodies are intended for use in the diagnosis, monitoring, prevention, and treatment of SARS-CoV-2 infection and associated diseases, such as COVID-19. He has 1 patent to his name.
Career Highlights
Throughout his career, Antoine Pau has worked with prestigious organizations, including Institut Pasteur and Spikimm. His experience in these institutions has allowed him to contribute to groundbreaking research in the field of infectious diseases.
Collaborations
Antoine has collaborated with notable colleagues, including Cyril Planchais and Hugo Mouquet. Their combined expertise has further advanced the research and development of effective treatments for viral infections.
Conclusion
Antoine Pau's innovative work in monoclonal antibodies represents a significant advancement in the fight against COVID-19. His contributions to biotechnology continue to have a lasting impact on public health.